Deep Brain Stimulation (DBS) attentional effects parallel those of l-dopa treatment

Brusa, L.; Pierantozzi, M.; Peppe, A.; Altibrandi, M. G.; Giacomini, P.; Mazzone, P.; Stanzione, P.
September 2001
Journal of Neural Transmission;Sep2001, Vol. 108 Issue 8/9, p1021
Academic Journal
Summary. Aim of our study was to investigate the different effects on attentional capacity of deep brain stimulation DBS (STN or GPi) and of l-dopa in PD patients. Patients were evaluated on-DBS/off-l-dopa, on-l-dopa/off-DBS, on-l-dopa/on-DBS and off-l-dopa/off-DBS. Our results indicate that DBS effects on attentional functions parallel those of l-dopa. A site independent (both STN and GPi) worsening of verbal fluency was observed, possibly connected to the stimulus effect on the cortico-subcortical-cortical loop.


Related Articles

  • Postural Sway and Effect of Levodopa in Early Parkinson's Disease. Beuter, Anne; Hernández, Roberto; Rigal, Robert; Modolo, Julien; Blanchet, Pierre J. // Canadian Journal of Neurological Sciences;Mar2008, Vol. 35 Issue 1, p65 

    Objective: To characterize postural stability control and levodopa responsiveness in early Parkinson's disease (PD). Methods: Postural sway was studied during quiet stance in ten patients within six years of PD onset, both before (OFF) and after (ON) regular oral levodopa dosing. Postural sway...

  • Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET. Hilker, R.; Voges, J.; Thiel, A.; Ghaemi, M.; Herholz, K.; Sturm, V.; Heiss, W.-D. // Journal of Neural Transmission;Oct2002, Vol. 109 Issue 10, p1257 

    Summary. In order to compare the effects of high-frequency stimulation of the subthalamic nucleus (STN-DBS) and a levodopa-challenge on cerebral metabolic activity, we conducted PET scans with [18F]2-fluoro-2-deoxyglucose (FDG) in the drug- and stimulation- on- and off-condition in a single...

  • Dopamine receptor agonists in the therapy of Parkinson’s disease. Foley, P.; Gerlach, M.; Double, K. L.; Riederer, P. // Journal of Neural Transmission;Oct2004, Vol. 111 Issue 10-11, p1375 

    Forty years after its introduction by Birkmayer and Hornykiewicz (1961),L-DOPA-based therapy of Parkinson’s disease remains the central pillar in the management of the disorder. Nevertheless, it is not unproblematic, and dopamine receptor agonists play increasingly important roles in...

  • Madopar.  // Royal Society of Medicine: Medicines;2002, p344 

    This article presents information on Madopar, a proprietary, prescription-only compound preparation of levodopa and benserazide hydrochloride, which is a combination called co-beneldopa. It can be used to treat parkinsonism, but not the parkinsonian symptoms induced by drugs. It is available as...

  • benserazide hydrochloride.  // Royal Society of Medicine: Medicines;2002, p104 

    The article presents information on benserazide hydrochloride which is an enzyme inhibitor which is administered therapeutically in combination with the drug levodopa to treat parkinsonism, but not the parkinsonian symptoms induced by drugs. Benserazide prevents levodopa being too rapidly broken...

  • Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease. Lees, Andrew // Drugs & Aging;2005, Vol. 22 Issue 9, p731 

    Parkinson’s disease (PD) is primarily a disease of elderly patients. This article reviews current knowledge and recent developments relating to drugs that can be used as alternatives to levodopa as initial treatment of PD. Synthetic orally acting dopamine agonists have found increasing...

  • Praktische Aspekte der Behandlung des idiopathischen Parkinsonsyndroms. Fuhr, Peter; Gschwandtner, Ute; Brunnschweiler, Heiner; Taub, Ethan // Praxis (16618157);8/7/2013, Vol. 102 Issue 16, p981 

    Correct diagnosis is the main problem at the beginning of Parkinson's disease. Treatment is symptomatic and begins with levodopa or dopamine agonists, depending on age and neuropsychiatrie symptoms. When many drug intakes are necessary or major non-motor problems are present, the situation...

  • A brief history of levodopa. Hornykiewicz, Oleh // Journal of Neurology;Nov2010, Vol. 257 Issue 2, p249 

    This article highlights some landmarks in the history of levodopa, beginning with its isolation in 1910-13 from seedlings of Vicia faba to the demonstration, in 1961, of its 'miraculous' effect in patients with Parkinson's disease (PD). Midway between these two time points, in 1938, l-dopa...

  • Deep brain stimulation surgery complicated by Parkinson hyperpyrexia syndrome. Landriel, Ezequiel Goldschmidt Federico; Ajler, Pablo; Ciraolo, Carlos // Neurology India;Nov2011, Vol. 59 Issue 6, p911 

    The article discusses the effectiveness of deep brain stimulation (DBS) in treating Parkinson-hyperpyrexia syndrome (PHS) in patients with Parkinson's disease (PD). It cites the case of a 59-year-old man, who has PD since 22 years old, presented for globus pallidus interna (GPi) DBS surgery. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics